Stratification of Systemic Lupus Erythematosus Patients Using Gene Expression Data to Reveal Expression of Distinct Immune Pathways - Deokar, Aditi (medRxiv, 2020)
Systemic lupus erythematosus (SLE) is the tenth leading cause of death in females 15-24 years old in the US. The diversity of symptoms and immune pathways expressed in SLE patients causes difficulties in treating SLE as well as in new clinical trials. This study used unsupervised learning on gene expression data from adult SLE patients to separate patients into clusters. The dimensionality of the gene expression data was reduced by three separate methods (PCA, UMAP, and a simple linear autoencoder) and the results from each of these methods were used to separate patients into six clusters with k-means clustering.The clusters revealed three separate immune pathways in the SLE patients that caused SLE. These pathways were: (1) high interferon levels, (2) high autoantibody levels, and (3) dysregulation of the mitochondrial apoptosis pathway. The first two pathways have been extensively studied in SLE. However, mitochondrial apoptosis has not been investigated before to the best of our knowledge as a standalone cause of SLE, independent of autoantibody production, indicating that mitochondrial proteins could lead to a new set of therapeutic targets for SLE in future research.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data used in this study was publicly available through the open-source GEO repository (accession number GSE138458). No primary data was collected in this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this study are available on GEO (accession number GSE138458) and were originally collected and referenced in the following study. Guthridge, J. M., Lu, R., Tran, L. T. H., Arriens, C., Aberle, T., Kamp, S., Munroe, M. E., Dominguez, N., Gross, T., DeJager, W., Macwana, S. R., Bourn, R. L., Apel, S., Thanou, A., Chen, H., Chakravarty, E. F., Merrill, J. T., & James, J. A. (2020). Adults with systemic lupus exhibit distinct molecular phenotypes in a cross-sectional study. EClinicalMedicine, 20, 100291. https://doi.org/10.1016/j.eclinm.2020.100291 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138458